Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Helus Pharma, the commercial name of Cybin Inc., has closed an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million. Cantor and Barclays acted as joint bookrunning managers, with Bloom Burton Securities Inc. and Lucid Capital Markets as lead managers.
The company plans to use the net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and general corporate purposes. Phase 3 APPROACH data for HLP003 are expected in the fourth quarter of 2026.
Positive
- None.
Negative
- None.
Insights
Helus secures $50M to fund late-stage NSA mental health pipeline.
Helus Pharma completed an underwritten sale of 10,309,280 common shares at US$4.85 each, raising gross proceeds of US$50 million. Underwriters received a US$3 million cash commission, indicating a standard marketed equity financing for a clinical-stage biotech.
The company earmarks proceeds to advance HLP003 (Phase 3 for major depressive disorder, with APPROACH data expected in Q4 2026), HLP004 (Phase 2 for generalized anxiety disorder), and the HLP005 program, plus working capital. These allocations concentrate new capital on late- and mid-stage NSA assets.
Forward-looking statements highlight typical development and macro risks, including clinical progress, NSA market expectations, regulatory constraints, and macroeconomic factors. Future disclosures on trial progress and data readouts, especially the Phase 3 APPROACH results in Q4 2026, will be key to understanding how effectively this capital raise supports Helus’ strategy.
Key Figures
Shares offered: 10,309,280 shares
Offering price: US$4.85 per share
Gross proceeds: US$50 million
+3 more
6 metrics
Shares offered
10,309,280 shares
Common shares sold in underwritten offering
Offering price
US$4.85 per share
Price per common share in the offering
Gross proceeds
US$50 million
Aggregate gross proceeds from the offering
Underwriters’ commission
US$3 million
Cash commission paid to underwriters
Registration form
Form F-10 (File No. 333-292294)
Filed under the U.S. Securities Act of 1933
Phase 3 data timing
Q4 2026
Expected APPROACH data for HLP003
Key Terms
underwritten offering, prospectus supplement, short form base shelf prospectus, Multijurisdictional Disclosure System, +2 more
6 terms
underwritten offering financial
"it has closed its previously announced underwritten offering of 10,309,280 common shares"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
prospectus supplement regulatory
"pursuant to a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
short form base shelf prospectus regulatory
"to the Company’s short form base shelf prospectus dated September 17, 2025, as amended"
A short form base shelf prospectus is a pre-approved, reusable document that lets a company register a pool of securities (like stocks or bonds) it can sell over time without repeating a full disclosure process each time. Think of it as a menu the company files once so it can quickly offer items from that menu later; investors care because it speeds up capital raises, can dilute existing holdings, and signals the company’s ability to access funding when needed.
Multijurisdictional Disclosure System regulatory
"in accordance with the Multijurisdictional Disclosure System established between Canada and the United States"
A multijurisdictional disclosure system is a regulatory framework that lets a company file one set of official documents and have them accepted by regulators in multiple countries, rather than preparing separate filings for each place. For investors, it means faster, more consistent access to a company’s financial reports and material news across borders, reducing delays and making it easier to compare information the way a single, shared form simplifies multiple applications.
Breakthrough Therapy Designation medical
"HLP003... in Phase 3 clinical development... that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
forward-looking statements regulatory
"Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2026.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | June 25, 2026 | By: | /s/ Greg Cavers | |||||||||||
| Name: | Greg Cavers | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
EXHIBIT INDEX
| 99.1 | News Release dated June 25, 2026 | ||||
HELUS PHARMATM ANNOUNCES CLOSING OF US$50 MILLION UNDERWRITTEN OFFERING
NEW YORK & TORONTO – June 25, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the “Offering”).
Cantor and Barclays acted as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets acted as lead managers for the Offering.
The Company intends to use the net proceeds from the Offering to progress the Company’s HLP003 for major depressive disorder with Phase 3 APPROACH data expected in the fourth quarter of 2026, HLP004 for generalized anxiety disorder, and HLP005 programs, and for working capital and general corporate purposes.
The Company offered the Common Shares only in the United States and in certain other jurisdictions outside of Canada, pursuant to a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025 (the “Base Shelf Prospectus”). The Prospectus Supplement was filed with the securities commissions in all of the provinces and territories of Canada and with the United States Securities and Exchange Commission (the “SEC”), as part of a registration statement on Form F-10 (File No. 333-292294) which was filed with the SEC, under the United States Securities Act of 1933, as amended, on December 19, 2025, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Base Shelf Prospectus, the Prospectus Supplement and the documents incorporated by reference therein, including any marketing materials, are available on the Company’s SEDAR+ profile at www.sedarplus.ca and the Company’s EDGAR profile at www.sec.gov/edgar. An electronic or paper copy of the Base Shelf Prospectus and the Prospectus Supplement may be obtained, without charge, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at (888) 603-5847, or via e-mail at Barclaysprospectus@broadridge.com.
In consideration for their services, the Company paid to the underwriters a cash commission of US$3 million.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Helus Pharma
Helus PharmaTM, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has a portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. Helus PharmaTM is a trademark of Helus Pharma Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s intended use of proceeds, and the Company’s ability to address the need for treatment options for people who suffer from depression, anxiety and other mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and the Company’s EDGAR profile at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004, and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
matthew.beck@astrpartners.com
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
matthew.beck@astrpartners.com
George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
FAQ
What did Helus Pharma (HELP) announce in this Cybin Inc. Form 6-K?
Helus Pharma announced it closed an underwritten public offering of 10,309,280 common shares at US$4.85 per share, raising US$50 million in gross proceeds. The update was furnished through a Form 6-K filed by Cybin Inc., Helus’ corporate parent.
How much capital did Helus Pharma (HELP) raise and on what terms?
Helus Pharma raised US$50 million in gross proceeds by selling 10,309,280 common shares at an offering price of US$4.85 per share. Underwriters received a cash commission of US$3 million for their services in connection with the underwritten offering.
How will Helus Pharma (HELP) use the US$50 million of offering proceeds?
Helus Pharma intends to use the net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, and for working capital and general corporate purposes. These allocations focus new capital on its core novel serotonergic agonist pipeline.
What are Helus Pharma’s lead NSA programs HLP003 and HLP004 targeting?
HLP003 is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has Breakthrough Therapy Designation from the U.S. FDA. HLP004 is in Phase 2 development for generalized anxiety disorder, expanding Helus Pharma’s focus on mental health conditions.
When is key clinical data expected for Helus Pharma’s HLP003 program?
Phase 3 APPROACH trial data for HLP003 in major depressive disorder are expected in the fourth quarter of 2026. This late-stage readout will be a major milestone for Helus Pharma’s lead novel serotonergic agonist and central to its mental health treatment strategy.